Regeneron receives positive trial results for CAPELLA

Regeneron Pharmaceutical's Phase 2 CAPELLA trial has turned in positive results.

The study was designed to assess the combination of aflibercept and rinucumab for the treatment of neovascular muscular degeneration related to age.

According to the data recovered from the study, the compound medication did not show in BCVA (best corrected visual acuity) at the 12-week mark, the study’s primary endpoint, compared to the injection monotherapy intravitreal aflibercept. A 5.8 BCVA letter improvement was reported in both groups receiving the aflibercept/rinucumab combination.

"EYLEA (aflibercept) injection is an established, effective therapy that has set a high bar in the treatment of wet AMD," Regeneron Chief Scientific Officer Dr. George Yancopoulos said. "The addition of rinucumab did not improve on the efficacy of aflibercept alone. We are committed to continuing to innovate for patients with serious vision-threatening diseases, and look forward to the results of our ongoing combination studies of aflibercept and nesvacumab, an anti-angiopoietin 2 antibody, for which the preclinical data is more supportive.”

The safety and effectiveness of EYLEA remained the same as in the Phase 3 study. CAPELLA’s effectiveness across all CNV subtypes were also consistent.